Drug Used to Treat Type 2 Diabetes Linked to Cancer, Heart Failure and Other Complications
DALLAS (November 17, 2015) – The national law firm of Baron & Budd is investigating the possibility of legal action involving the drug Onglyza, which is used to help Type 2 diabetics control their blood sugar levels. The medication has been linked to pancreatic cancer, heart failure and other serious health complications.
Onglyza, the brand name for the drug saxagliptin, is manufactured by the pharmaceutical company AstraZeneca. The medication is classified as a DPP-4 inhibitor, and works by helping to increase the production of insulin as well as reduce the amount of sugar produced by the liver. DPP-4 is an enzyme produced by the body to break down a hormone known as GLP-1. This hormone instructs the pancreas to produce more insulin. However, diabetics do not have enough insulin in their bodies. As a result, they have too much sugar in their blood. Onglyza is designed to prevent DPP-4 from breaking down GLP-1, allowing the pancreas to produce more insulin.
The U.S. Food and Drug Administration (FDA) approved Onglyza in 2009, but a 2013 study in the medical journal Diabetics showed that DPP-4 inhibitors such as Onglyza could increase a patient’s risk for developing pancreatic cancer. In addition, an FDA panel recommended in April 2015 that the warning label of the drug be changed to add an increased risk of heart failure. In August 2015, the agency added a safety warning for Onglyza and other DPP-4 inhibitors, citing an increased risk of severe joint pain for patients using the medications.
“We are taking a close look to determine whether or not the rights of diabetic patients taking Onglyza were violated due to not being warned of the risks of the medication,” said Russell Budd, president and managing shareholder of the national law firm of Baron & Budd. “Our firm is committed to ensuring that all patients are protected when taking drugs that are supposed to help them, not hurt them.”
About Baron & Budd, P.C.
The law firm of Baron & Budd, P.C., with offices in Dallas, Baton Rouge, New Orleans, Austin and Los Angeles, is a nationally recognized law firm with a nearly 40-year history of "Protecting What’s Right" for people, communities and businesses harmed by negligence. Baron & Budd’s size and resources enable the firm to take on large and complex cases. The firm represents individuals and government and business entities in areas as diverse as dangerous pharmaceuticals and medical devices, environmental contamination, the Gulf oil spill, financial fraud, overtime violations, deceptive advertising, automotive defects, trucking accidents, nursing home abuse, and asbestos-related illnesses such as mesothelioma.